See more : Chang Lan Electric Technology Co.,Ltd. (002879.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Veru Inc. (VERU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Veru Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dynagreen Environmental Protection Group Co., Ltd. (1330.HK) Income Statement Analysis – Financial Results
- Frasers Centrepoint Trust (J69U.SI) Income Statement Analysis – Financial Results
- Cloud DX Inc. (CDXFF) Income Statement Analysis – Financial Results
- PT Bumi Resources Minerals Tbk (BRMS.JK) Income Statement Analysis – Financial Results
- Shenzhen Institute of Building Research Co., Ltd. (300675.SZ) Income Statement Analysis – Financial Results
Veru Inc. (VERU)
About Veru Inc.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.89M | 16.30M | 39.35M | 61.26M | 42.59M | 31.80M | 15.86M | 13.66M | 22.13M | 32.60M | 24.49M | 31.46M | 35.03M | 18.57M | 22.22M | 27.54M | 25.63M | 19.32M | 14.82M | 11.16M | 8.83M | 9.05M | 8.42M | 6.72M | 5.77M | 4.72M | 5.45M | 2.92M | 2.06M | 2.20M | 16.20M | 12.50M | 11.20M | 13.10M | 10.70M |
| Cost of Revenue | 11.03M | 8.73M | 8.76M | 13.33M | 11.81M | 10.15M | 7.08M | 6.64M | 8.78M | 13.63M | 11.37M | 13.95M | 14.41M | 8.70M | 9.30M | 14.03M | 14.90M | 12.16M | 9.33M | 6.37M | 5.21M | 5.46M | 4.86M | 5.34M | 3.60M | 3.31M | 5.27M | 3.48M | 3.68M | 2.50M | 7.50M | 6.90M | 6.10M | 7.20M | 6.10M |
| Gross Profit | 5.85M | 7.57M | 30.59M | 47.93M | 30.79M | 21.66M | 8.78M | 7.02M | 13.35M | 18.97M | 13.12M | 17.50M | 20.62M | 9.87M | 12.92M | 13.52M | 10.73M | 7.16M | 5.49M | 4.79M | 3.62M | 3.59M | 3.56M | 1.38M | 2.16M | 1.40M | 178.03K | -559.30K | -1.62M | -300.00K | 8.70M | 5.60M | 5.10M | 5.90M | 4.60M |
| Gross Profit Ratio | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.10% | 55.36% | 51.40% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53.14% | 58.16% | 49.08% | 41.86% | 37.04% | 37.03% | 42.93% | 41.03% | 39.67% | 42.31% | 20.52% | 37.49% | 29.70% | 3.27% | -19.18% | -78.50% | -13.64% | 53.70% | 44.80% | 45.54% | 45.04% | 42.99% |
| Research & Development | 12.81M | 51.20M | 70.65M | 32.69M | 16.94M | 13.74M | 10.85M | 3.50M | 99.39K | 219.82K | 5.58K | 4.75K | 5.28K | 10.93K | 381.00 | 105.92K | 284.22K | 208.61K | 210.88K | 273.78K | 179.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 361.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.02M | 8.66M | 12.13M | 9.14M | 7.49M | 9.63M | 6.23M | 6.43M | 7.01M | 7.04M | 5.89M | 4.82M | 5.71M | 4.46M | 4.89M | 4.93M | 1.85M | 2.97M | 3.14M | 2.90M | 3.04M | 2.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.27K | 88.87K | 0.00 | 58.12K | 221.72K | 52.95K | 332.76K | 220.18K | 191.15K | 223.80K | 179.87K | 218.50K | 123.10K | 47.60K | 36.53K | 43.83K | 129.16K | 0.00 | 0.00 | 433.82K | 1.64M | 2.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.07M | 8.75M | 12.13M | 9.20M | 7.71M | 9.68M | 6.56M | 6.65M | 7.20M | 7.26M | 6.07M | 5.04M | 5.83M | 4.51M | 4.92M | 4.97M | 1.98M | 2.97M | 3.14M | 3.33M | 4.68M | 5.97M | 8.00M | 10.70M | 8.10M | 6.20M | 7.10M | 3.70M |
| Other Expenses | -1.22M | 2.09M | -316.06K | -8.71M | 14.10M | -5.89M | -2.20M | 15.51M | 9.20M | 9.20M | 9.20M | 7.71M | 2.01M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 1.83M | 1.28M | 0.00 | 0.00 | 0.00 | 100.00K | 500.00K | 400.00K | 300.00K | 200.00K | 100.00K |
| Operating Expenses | 42.77M | 101.35M | 113.81M | 53.36M | 45.53M | 28.09M | 29.65M | 14.58M | 10.33M | 12.35M | 9.20M | 7.71M | 9.68M | 6.57M | 6.65M | 7.30M | 7.55M | 6.28M | 5.25M | 6.10M | 4.69M | 4.92M | 6.23M | 1.98M | 4.80M | 4.43M | 3.33M | 4.68M | 6.33M | 8.10M | 11.20M | 8.50M | 6.50M | 7.30M | 3.80M |
| Cost & Expenses | 53.80M | 110.08M | 122.58M | 66.70M | 57.34M | 38.24M | 36.74M | 21.21M | 19.11M | 25.99M | 20.57M | 21.67M | 24.09M | 15.27M | 15.94M | 21.33M | 22.45M | 18.44M | 14.58M | 12.47M | 9.90M | 10.38M | 11.09M | 7.32M | 8.41M | 7.74M | 8.60M | 8.15M | 10.01M | 10.60M | 18.70M | 15.40M | 12.60M | 14.50M | 9.90M |
| Interest Income | 0.00 | 0.00 | 4.37M | 4.89M | 4.62M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.17K | 55.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 607.47K | 2.43M | 4.37M | 4.85M | 4.62M | 4.71M | 2.95M | 2.04M | 3.32M | 0.00 | 50.57K | 0.00 | 296.18K | 124.63K | 3.98M | 2.39M | 0.00 | 74.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 268.18K | 269.87K | 209.60K | 593.87K | 783.64K | 471.42K | 452.05K | 481.01K | 422.87K | 494.26K | 589.34K | 556.30K | 461.45K | 464.91K | 466.54K | 268.38K | 217.09K | 252.94K | 333.63K | 522.80K | 1.09M | 1.55M | 1.01M | 923.92K | 1.83M | 1.28M | 533.99K | 553.30K | 675.08K | -100.00K | -500.00K | -400.00K | -300.00K | -200.00K | -100.00K |
| EBITDA | -36.20M | -89.98M | -79.23M | 9.75M | -14.65M | -7.14M | -19.67M | -8.12M | 4.92M | 7.11M | 4.51M | 10.35M | 11.40M | 3.76M | 4.69M | 5.32M | 3.40M | 1.01M | 573.99K | -1.11M | 19.17K | 210.53K | -1.66M | 321.06K | -812.89K | -1.74M | -2.73M | -4.76M | -7.10M | -8.30M | -2.20M | -2.50M | -1.10M | -1.60M | 800.00K |
| EBITDA Ratio | -214.38% | -552.10% | -211.47% | -38.93% | -34.62% | -20.24% | -131.57% | -44.52% | 16.22% | 21.64% | 18.77% | 33.21% | 31.65% | 18.08% | 39.04% | 26.99% | 9.08% | 6.19% | 3.96% | -6.94% | 0.94% | 2.33% | -4.75% | 2.98% | -16.61% | -39.07% | -50.15% | -163.37% | -340.18% | -377.27% | -13.58% | -20.00% | 8.93% | -12.21% | 7.48% |
| Operating Income | -36.92M | -93.78M | -83.22M | -5.44M | -14.75M | -6.44M | -20.87M | -8.49M | 3.02M | 6.62M | 3.92M | 9.79M | 10.94M | 3.30M | 4.35M | 4.72M | 3.18M | 875.91K | 240.36K | -1.31M | -1.07M | -1.34M | -2.67M | -602.86K | -2.64M | -3.03M | -3.15M | -5.24M | -7.95M | -8.20M | -1.70M | -2.10M | 1.30M | -1.40M | 900.00K |
| Operating Income Ratio | -218.61% | -575.46% | -211.47% | -8.88% | -34.62% | -20.24% | -131.57% | -62.20% | 13.64% | 20.30% | 16.02% | 31.12% | 31.23% | 17.75% | 19.57% | 17.13% | 12.42% | 4.53% | 1.62% | -11.75% | -12.09% | -14.76% | -31.72% | -8.98% | -45.75% | -64.17% | -57.80% | -179.62% | -385.12% | -372.73% | -10.49% | -16.80% | 11.61% | -10.69% | 8.41% |
| Total Other Income/Expenses | -160.93K | 1.11M | -316.06K | -8.71M | -5.31M | -5.89M | -2.20M | -108.38K | -204.60K | 68.63K | 33.28K | 144.26K | -147.91K | -63.37K | -125.03K | 332.10K | 1.02M | -7.00K | -12.35K | -44.40K | 0.00 | 0.00 | -1.26M | -568.40K | 145.20K | 100.18K | 117.14K | 79.53K | -252.61K | 0.00 | 1.00M | 0.00 | 600.00K | 400.00K | 200.00K |
| Income Before Tax | -37.08M | -92.67M | -83.54M | 4.27M | -20.05M | -12.32M | -23.07M | -8.60M | 2.81M | 6.69M | 3.96M | 9.93M | 10.79M | 3.23M | 4.22M | 5.05M | 4.20M | 868.91K | 228.01K | -1.33M | -1.07M | 0.00 | -3.93M | -1.17M | -2.49M | -2.93M | -3.03M | -5.16M | -8.20M | 0.00 | -1.50M | 0.00 | -800.00K | -1.00M | 1.00M |
| Income Before Tax Ratio | -219.56% | -568.65% | -212.28% | 6.96% | -47.08% | -38.74% | -145.43% | -63.00% | 12.72% | 20.51% | 16.16% | 31.58% | 30.80% | 17.41% | 19.01% | 18.34% | 16.40% | 4.50% | 1.54% | -11.87% | -12.09% | 0.00% | -46.67% | -17.44% | -43.23% | -62.05% | -55.65% | -176.89% | -397.36% | 0.00% | -9.26% | 0.00% | -7.14% | -7.63% | 9.35% |
| Income Tax Expense | 725.10K | 480.21K | 236.40K | -3.13M | -1.08M | -303.93K | 866.10K | -1.99M | 2.47M | 2.34M | 1.52M | -4.41M | -4.51M | -2.17M | -2.51M | -1.49M | -762.86K | -825.00K | -29.32K | 58.51K | 1.02M | 1.04M | 2.07M | 447.43K | 906.65K | 624.13K | 89.28K | 291.21K | 963.00K | 100.00K | 1.30M | 1.60M | 5.60M | 100.00K | 600.00K |
| Net Income | -37.80M | -93.15M | -83.78M | 7.39M | -18.97M | -12.02M | -23.94M | -6.61M | 344.73K | 4.35M | 2.43M | 14.34M | 15.30M | 5.40M | 6.74M | 6.54M | 4.97M | 1.69M | 282.03K | -1.36M | -2.02M | -2.37M | -3.48M | -1.17M | -3.69M | -3.75M | -3.36M | -5.61M | -8.66M | -8.30M | -3.00M | -3.70M | -4.30M | -1.50M | 300.00K |
| Net Income Ratio | -223.86% | -571.60% | -212.88% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29.08% | 30.32% | 23.73% | 19.38% | 8.77% | 1.90% | -12.15% | -22.87% | -26.20% | -41.36% | -17.44% | -63.99% | -79.53% | -61.59% | -192.33% | -419.54% | -377.27% | -18.52% | -29.60% | -38.39% | -11.45% | 2.80% |
| EPS | -0.28 | -1.10 | -1.05 | 0.10 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.09 | 0.51 | 0.55 | 0.20 | 0.25 | 0.25 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| EPS Diluted | -0.28 | -1.10 | -1.05 | 0.09 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.08 | 0.50 | 0.53 | 0.19 | 0.24 | 0.24 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| Weighted Avg Shares Out | 134.88M | 84.97M | 80.12M | 76.27M | 66.75M | 63.32M | 53.86M | 34.41M | 28.67M | 28.53M | 28.52M | 28.38M | 27.69M | 27.29M | 26.98M | 25.65M | 26.12M | 24.95M | 23.80M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
| Weighted Avg Shares Out (Dil) | 134.88M | 84.97M | 80.12M | 83.80M | 66.75M | 63.32M | 53.86M | 34.64M | 28.93M | 28.92M | 28.87M | 28.73M | 28.93M | 28.97M | 28.55M | 27.81M | 27.98M | 26.40M | 26.49M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders
MIAMI, FL, June 17, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, would...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
MIAMI, FL, June 10, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru to Present at the Jefferies Global Healthcare Conference
MIAMI, FL, May 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Announces Steven B. Heymsfield M.D.
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
MIAMI, FL, May 14, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
--Phase 2b clinical study of enobosarm in combination with semaglutide (Wegovy ® * ) for high quality weight loss is actively enrolling-- --Company assembles esteemed high quality weight loss Scientific Advisory Board – five MDs with significant relevant medical, clinical...
Veru to Present at the GLP-1 Based Therapeutics Summit
MIAMI, FL, May 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today...
Source: https://incomestatements.info
Category: Stock Reports